Kelly Lawrence W & Associates’s GSK GSK Stock Holding History

Kelly Lawrence W & Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2	Closed	–	–	160
2017 Q1	$0	Buy	+2	New	+$101	﹤0.01%	192

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Kelly Lawrence W & Associates's GSK Position: Q2 2017 in Review

Kelly Lawrence W & Associates sold out of GSK (GSK) in Q2 2017, closing a stake of 2 shares.

Kelly Lawrence W & Associates first reported a position in GSK in Q1 2017 and held it in 1 quarter. The position peaked at $0 in Q1 2017. 779 funds tracked by Wall St. Rank hold GSK as of Q2 2017.

Kelly Lawrence W & Associates reported no remaining GSK position as of Q2 2017 after selling out during the quarter.
Kelly Lawrence W & Associates sold 2 GSK shares in Q2 2017.
Kelly Lawrence W & Associates first reported a position in GSK in Q1 2017 and held it in 1 quarter.
Kelly Lawrence W & Associates's GSK position peaked at $0 in Q1 2017.
779 funds tracked by Wall St. Rank held GSK as of Q2 2017.

Based on Kelly Lawrence W & Associates's 13F filing for Q2 2017, filed 1 Aug 2017.